Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus

Research in Experimental Medicine

Volumn 199, Issue 5, 1999, Pages 253-262

  Walli, Ravi ^a   Michl, Gerlinde M ^a   Mühlbayer, Dieter ^b   Brinkmann, Lars ^a   Goebel, Frank D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034051079     PISSN: 03009130     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004330050123     Document Type: Article

References (24)

1. 1. Bailey CJ (1988) Metformin revisited: its actions and indications for use. Diabet Med 5: 315-320
2. 2. Bloomgarden ZT (1998) Insulin resistance: current concepts. Clin Ther 20: 216-231
3. 3. Brinkman K, Smeitink JA, Romijn JA, et al (1999) Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115
4. 4. Carr A, Samaras K, Burton S, et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-58
5. 5. Cremer P, Nagel D, Labrot B, et al (1994) Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24: 444-453
6. 6. Gelding SV, Robinson S, Lowe S, Niththyananthan R, Johnston DG (1994) Validation of the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol (Oxf) 40: 611-615
7. 7. Ghazzi MN, Perez JE, Antonucci TK, et al (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46: 433-439
8. 8. Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37: 693-707
9. 9. Granberry MC, Fonseca VA (1999) Insulin resistance syndrome: options for treatment. South Med J 92: 2-15
10. 10. Granberry MC, Schneider EF, Fonseca VA (1998) The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy 18: 973-987
11. 11. Inzucchi SE, Maggs DG, Spollett GR, et al (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus [see comments]. N Engl J Med 338: 867-872
12. 12. Janssen M, Rillaerts E, De Leeuw I (1991) Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 45: 363-367
13. 13. Kumar S, Boulton AJ, Beck Nielsen H, et al (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39: 701-709
14. 14. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE (1997) Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 54: 801-808
15. 15. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M (1998) Body shape changes in HIV-infected patients [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 19: 307-308
16. 16. Saint-Marc T, Touraine JL (1998) Truncal adiposity sydrome hyperinsulinemia, endocrine and metabolic disorders in patients receiving HIV protease inhibitors (abstract). AIDS: S54
17. 17. Saint-Marc T, Touraine JL (1999) Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13: 1000-1002
18. 18. Schwartz S, Raskin P, Fonseca V, Graveline JF (1998) Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group [see comments]. N Engl J Med 338: 861-866
19. 19. Segal KR, Burastero S, Chun A, Coronel P, Pierson RN Jr, Wang J (1991) Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement [see comments]. Am J Clin Nutr 54: 26-29
20. 20. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD (1999) Hyperlipidemia under therapy with protease inhibitors. Infection 27: 77-81
21. 21. Shaw AJ, McLean KA, Evans BA (1998) Disorders of fat distribution in HIV infection. Int J STD AIDS 9: 595-599
22. 22. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514
23. 23. Viraben R, Aquilina C (1998) Indinavir-associated lipodystrophy. AIDS 12: F37-39
24. 24. Walli R, Herfort O, Michl GM, et al (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12: